Tian, Y., Advances in the heterologous biosynthesis of QS saponins: a review. Microb Cell Fact. 2026 May 26. PMID: 42192394

This review paper provides a comprehensive overview of recent advances in the heterologous biosynthesis of QS saponins, with a particular focus on QS-21. It highlights the significance of QS-21 in enhancing immune responses in vaccines, especially for diseases like influenza, COVID-19, and various cancers, emphasizing its broad biomedical applications. The paper is unique in systematically summarizing the biosynthetic pathways of QS saponins and discussing cutting-edge synthetic biology strategies employed to produce these complex molecules in microbial factories, addressing current bottlenecks such as low yields and enzymatic inefficiencies.

Comment from DKI: While it does not provide specific cost comparisons, it emphasizes that chemical synthesis of QS-21 is complex, expensive, and inefficient due to the molecule's intricate structure (requiring numerous steps, e.g., 76 steps in
total synthesis). In contrast, heterologous biosynthesis using engineered microbial systems, as discussed in the paper, has the potential to reduce costs through scalable, sustainable production. Therefore, although current synthetic QS-21
production remains cost-prohibitive relative to natural bark extraction, advancements in bioengineering and metabolic pathway optimization may make microbial-based production more economical in the future, potentially leading to comparable to bark-
derived QS-21. However, as it is now, bark-based QS-21 production remains the most practical and effective option for vaccine development.

Click here to access the full scientific paper.